348 related articles for article (PubMed ID: 17144774)
1. The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived.
Weissert R
Expert Rev Neurother; 2006 Nov; 6(11):1587-90. PubMed ID: 17144774
[No Abstract] [Full Text] [Related]
2. Multiple sclerosis poses tough drug development challenges.
Senior K
Drug Discov Today; 2005 Dec; 10(23-24):1583-4. PubMed ID: 16376813
[No Abstract] [Full Text] [Related]
3. [Fingolimod - a new immunomodulator].
Friedrich FW; Eschenhagen T
Dtsch Med Wochenschr; 2009 Oct; 134(42):2127-31. PubMed ID: 19809964
[TBL] [Abstract][Full Text] [Related]
4. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
Hecht B
Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402
[TBL] [Abstract][Full Text] [Related]
5. Fingolimod: a novel immunosuppressant for multiple sclerosis.
Brown BA; Kantesaria PP; McDevitt LM
Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617
[TBL] [Abstract][Full Text] [Related]
6. FTY720 (fingolimod) for relapsing multiple sclerosis.
Horga A; Montalban X
Expert Rev Neurother; 2008 May; 8(5):699-714. PubMed ID: 18457527
[TBL] [Abstract][Full Text] [Related]
7. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
8. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
9. [New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].
Komoly S
Ideggyogy Sz; 2012 Nov; 65(11-12):421-2. PubMed ID: 23289178
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
O'Day K; Meyer K; Miller RM; Agarwal S; Franklin M
J Med Econ; 2011; 14(5):617-27. PubMed ID: 21777161
[TBL] [Abstract][Full Text] [Related]
11. Fingolimod for multiple sclerosis.
Pelletier D; Hafler DA
N Engl J Med; 2012 Jan; 366(4):339-47. PubMed ID: 22276823
[No Abstract] [Full Text] [Related]
12. FTY720 (fingolimod) in renal transplantation.
Budde K; Schütz M; Glander P; Peters H; Waiser J; Liefeldt L; Neumayer HH; Böhler T
Clin Transplant; 2006; 20 Suppl 17():17-24. PubMed ID: 17100697
[TBL] [Abstract][Full Text] [Related]
13. Fingolimod. Mitsubishi Pharma/Novartis.
Dumont FJ
IDrugs; 2005 Mar; 8(3):236-53. PubMed ID: 15772896
[TBL] [Abstract][Full Text] [Related]
14. [Emerging treatments for multiple sclerosis].
Nau JY
Rev Med Suisse; 2010 Jun; 6(251):1162-3. PubMed ID: 20572362
[No Abstract] [Full Text] [Related]
15. Emerging disease-modifying oral therapies for multiple sclerosis.
Losy J; Kalinowska-Łyszczarz A
J Neuroimmunol; 2011 Feb; 231(1-2):15-22. PubMed ID: 20947176
[TBL] [Abstract][Full Text] [Related]
16. New oral drugs for multiple sclerosis.
Gasperini C; Ruggieri S
Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
[TBL] [Abstract][Full Text] [Related]
17. Fingolimod: cardiovascular deaths.
Prescrire Int; 2012 Apr; 21(126):99. PubMed ID: 22515137
[No Abstract] [Full Text] [Related]
18. Multiple sclerosis: closing in on an oral treatment.
Martin R
Nature; 2010 Mar; 464(7287):360-2. PubMed ID: 20237554
[No Abstract] [Full Text] [Related]
19. Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis.
Johnson TA; Lapierre Y; Bar-Or A; Antel JP
Arch Neurol; 2010 Dec; 67(12):1449-55. PubMed ID: 21149809
[TBL] [Abstract][Full Text] [Related]
20. [FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].
Klatt J; Hartung HP; Hohlfeld R
Nervenarzt; 2007 Oct; 78(10):1200-8. PubMed ID: 17668161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
